Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
43 hedge funds and large institutions have $154M invested in Sienna Biopharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
26% more funds holding
Funds holding: 34 → 43 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less capital invested
Capital invested by funds: $178M → $154M (-$23.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.92M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.48M |
| 3 |
Morgan Stanley
New York
|
+$1.4M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.01M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$721K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$556K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$440K |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$332K |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$316K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$153K |
SNNA Hedge Fund Activity: Q4 2017 in Review
43 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q4 2017, worth a combined $154M — down 13% from $178M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SNNA positions and 3 closed out — a net gain of 9 holders — while 18 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $5.92M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $556K sold.
- 43 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q4 2017, up from 34 in Q3 2017.
- Funds reported $154M of Sienna Biopharmaceuticals, Inc. stock for Q4 2017, down 13% quarter-over-quarter.
- 12 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q4 2017 and 3 closed out, a net change of +9 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q4 2017 was BlackRock, an estimated $5.92M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q4 2017 was Laurion Capital Management, an estimated $556K sold.
Based on aggregated 13F filings for Q4 2017.